Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

Odontogenic myxoma (OM) is a rare benign tumor originating from the odontogenic mesenchyme, characterized by locally aggressive behavior in the jaw bones. We present a case report of a 36-year-old ...

A new review was published in Oncotarget, Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." In this review article, Dinara Ryspayeva and colleagues from Brown ...

An update from CStone Pharmaceuticals ( ($HK:2616) ) is now available. CStone Pharmaceuticals announced its participation in the AACR 2025 Annual ...

Oregon State University scientists have developed a highly efficient, uniquely shaped magnetic nanoparticle that could enable ...

Liver cancer, predominantly hepatocellular carcinoma (HCC), remains one of the most aggressive and leading causes of ...

Genelux Corporation’s GNLX share price has dipped by 12.21%, which has investors questioning if this is right time to buy.

Stock analysts at StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the ...

Burning Rock Biotech Limited’s BNR share price has dipped by 12.36%, which has investors questioning if this is right time to ...

New, improved formulation set to replace EGRIFTA SV®MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the ...

New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-s ...